BioPorto is a commercial-stage diagnostic company with a portfolio of antibodies and other products sold for research and diagnostic purposes. However, its lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The test should provide superior results to the standard of care (serum creatinine, sCr) in two hours versus 24 hours or more. We initiate at DKK1,078m or DKK6.93 per share.
22 Aug 2018
BioPorto Diagnostics - Altering the paradigm for kidney injury
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BioPorto Diagnostics - Altering the paradigm for kidney injury
BioPorto is a commercial-stage diagnostic company with a portfolio of antibodies and other products sold for research and diagnostic purposes. However, its lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The test should provide superior results to the standard of care (serum creatinine, sCr) in two hours versus 24 hours or more. We initiate at DKK1,078m or DKK6.93 per share.